ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "proteomics"

  • Abstract Number: 1400 • ACR Convergence 2021

    Analyses of Plasma Inflammatory Proteins Reveal Biomarkers Predictive of Subsequent Development of Giant Cell Arteritis; A Nested Case-Control Study

    Karin Wadström1, Jan-Åke Nilsson1, Aladdin Mohammad2, Kenneth Warrington3, Eric Matteson4, Magnus Jakobsson2, Lennart Jacobsson5 and Carl Turesson6, 1Lund University, Malmö, Sweden, 2Lund University, Lund, Sweden, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic College of Medicine and Science, Rochester, MN, 5University of Gothenburg, Gothenburg, Sweden, 6Lund University, Malm, Sweden

    Background/Purpose: Previous studies have demonstrated that metabolic factors may predispose to giant cell arteritis (GCA). The purpose of this study was to investigate the relation…
  • Abstract Number: 1434 • ACR Convergence 2021

    Multiomic Study of Skin, Peripheral Blood and Serum: Is Serum Proteome a Reflection of Disease Process at the End-Organ Level in Systemic Sclerosis?

    Victor Farutin1, Elma Kurtagic2, Joel Pradines3, Ishan Capila3, Maureen Mayes4, Minghua Wu5, Anthony Manning3 and Shervin Assassi6, 1Janssen R&D, LLC, Watertown, MA, 2Janssen R&D, LLC, Cambridge, 3Momenta Pharmaceuticals, Inc., Cambridge, MA, 4Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 5University of Texas Health Science Center at Houston, Houston, TX, 6University of Texas McGovern Medical School at Houston, Houston, TX

    Background/Purpose: Discovery of biomarkers in systemic sclerosis (SSc) represents an unmet clinical need. Samples from prominently affected fibrotic end-organs such as lung and skin are…
  • Abstract Number: 1816 • ACR Convergence 2021

    Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study

    Thierry Sornasse1, Jaclyn Anderson2, Koji Kato3, Apinya Lertratanakul4, Christopher Ritchlin5 and Iain McInnes6, 1AbbVie Inc, Redwood City, CA, 2AbbVie Inc, Gurnee, IL, 3AbbVie Inc, Shinagawa- Ku, Japan, 4AbbVie Inc., North Chicago, IL, 5Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, 6University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

    Background/Purpose: Treatment of non-biologic-DMARD-IR (DMARD-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in improvement in musculoskeletal symptoms,…
  • Abstract Number: 1858 • ACR Convergence 2021

    Serum Interferon Score Is a Biomarker of Active Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis Enrolled in the Prospective Registry of Early Systemic Sclerosis (PRESS) Cohort

    Monique Hinchcliff1, Suiyuan Huang2, Shervin Assassi3, Elana Bernstein4, Flavia Castelino5, Robyn Domsic6, Tracy Frech7, Jessica Gordon8, Faye Hant9, Ami Shah10, Victoria Shanmugam11, Virginia Steen12, Dinesh Khanna2 and Francesco Del Galdo13, 1Yale School of Medicine, Westport, CT, 2University of Michigan, Ann Arbor, MI, 3University of Texas McGovern Medical School at Houston, Houston, TX, 4Columbia University, New York, NY, 5Massachusetts General Hospital, Boston, MA, 6University of Pittsburgh, Pittsburgh, PA, 7University of Utah, Salt Lake City, UT, 8Hospital for Special Surgery, New York, NY, 9Medical University of South Carolina, Charleston, SC, 10Johns Hopkins Rheumatology, Baltimore, MD, 11The George Washington University, Great Falls, VA, 12Division of Rheumatology, Georgetown University, Washington, DC, 13University of Leeds, Leeds, United Kingdom

    Background/Purpose: Several published studies have demonstrated activation of the interferon type 1 (IFN) pathway in sera from patients with systemic sclerosis (SSc). Specifically, levels of…
  • Abstract Number: 0037 • ACR Convergence 2021

    Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis

    Lucía Lourido1, Cristina Ruiz-Romero2, Lidia Collado1, Monika Hansson3, Lars Klareskog4, Ronald Sjöberg5, Elisa Pin5, Peter Nilsson5 and Francisco Blanco-García6, 1Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España., A Coruña, Spain, 2Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, 3Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 5Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology & SciLifeLab, Stockholm, Sweden, 6Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain

    Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPAs) is a highly specific hallmark of rheumatoid arthritis (RA), that is present also in early disease. However,…
  • Abstract Number: 0029 • ACR Convergence 2020

    Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis

    Emma Weeding1, Andrea Fava1, Jill Buyon2, H. Michael Belmont3, Peter Izmirly4, Robert Clancy5, Jose Monroy-Trujillo6, Derek Fine6, William Apruzzese7, Harald Mischak8 and Michelle Petri9, 1Johns Hopkins University, Baltimore, MD, 2Department of Medicine, NYU School of Medicine, New York, NY, 3NYU School of Medicine, New York, NY, 4Department of Medicine, New York University School of Medicine, New York, NY, 5New York University School of Medicine, New York, NY, 6Johns Hopkins University, Baltimore, 7., Boston, 8Multiple Institutions, Glasgow, United Kingdom, 9Johns Hopkins University School of Medicine, Baltimore

    Background/Purpose: Current management of lupus nephritis (LN) is guided by histopathological features on kidney biopsy and measurement of proteinuria. Urine proteomics is a non-invasive source…
  • Abstract Number: 0038 • ACR Convergence 2020

    Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study

    Ana Fernandes1, Atlas Mashayekhi Sardoo2, Miguel Bernardes3, Patrícia Pinto4, Helena Santos5, João Lagoas Gomes6, José Tavares-Costa7, José A. P. da Silva8, João Madruga-Dias9, Alexandra Bernardo10, Jean-Charles Gaillard11, Lúcia Domingues12, Sara Maia12, Jean Armengaud11, Jaime C. Branco13, Ana Varela Coelho14 and Fernando Pimentel-Santos15, 11.Instituto de Tecnologia Química e Biológica, Universidade NOVA de Lisboa; 2.Universidade de Trás-os-Montes e Alto Douro, Vila Real, Portugal, Oeiras, Portugal, 23. CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisbon, Portugal, 34.Centro Hospitalar de S. João (Rheumatology Department) , Porto, Portugal, Porto, Portugal, 45. Centro Hospitalar de Vila Nova de Gaia/Espinho (Rheumatology Department), Vila Nova de Gaia, Portugal, Vila Nova de Gaia, Portugal, 56.Instituto Português de Reumatologia (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, 67.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, 78.Unidade Local de Saúde do Alto Minho (Rheumatology Department), Ponte de Lima, Portugal, Ponte de Lima, Portugal, 89.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, 910.Centro Hospital Médio Tejo (Rheumatology Department), Torres Novas, Portugal, Dublin, Ireland, 105.Centro Hospitalar de Vila Nova de Gaia/Espinho (Rheumatology Department), Vila Nova de Gaia, Portugal, Vila Nova de Gaia, Portugal, 1111.Centre d énergie atomique (Laboratoire Innovations technologiques pour la Détection et le Diagnostic (Li2D), Service de Pharmacologie et Immunoanalyse (SPI)), Avignon, France, Avignon, France, 123.CEDOC, NOVA Medical School. Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisboa, Portugal, 133.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, 141.Instituto de Tecnologia Química e Biológica, Universidade NOVA de Lisboa, Oeiras, Portugal, Oeiras, Portugal, 153.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisbon, Portugal

    Background/Purpose: Axial Spondyloarthritis (AS) is amongst the most common forms of inflammatory arthritis. Widely used in the treatment of axSpA, adalimumab is an engineered antibody…
  • Abstract Number: 0502 • ACR Convergence 2020

    Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis

    Sara Rahmati1, Fatima Abji1, Proton Rahman2 and Vinod Chandran3, 1University Health Network, Toronto, ON, Canada, 2Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic Arthritis (PsA) is a progressive inflammatory arthritis that occurs in about 24% of psoriasis patients. Early diagnosis of PsA is associated with better…
  • Abstract Number: 0513 • ACR Convergence 2020

    Mass Spectrometry Identifies Novel Biomarkers in Giant Cell Arteritis, Useful in Patients on Interleukin-6 Receptor Blockade

    Sebastian Unizony1, Robert Morris2, Johannes Kreuzer2, Wilhelm Haas2 and John H. Stone1, 1Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA

    Background/Purpose: We aimed to identify biomarkers of disease activity in giant cell arteritis (GCA) patients treated with prednisone monotherapy and with prednisone in combination with…
  • Abstract Number: 0752 • ACR Convergence 2020

    Serum Proteomics Implicates Neutrophil Degranulation in Rheumatoid Arthritis Disease Activity

    Liam O'Neil1, Vidyanand Anaparti1, Dana Wiens1, Irene Smolik1, Xiaobo Meng1 and Hani El-Gabalawy1, 1University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Though targeted therapeutics have improved outcomes in Rheumatoid Arthritis (RA) treatment, the understanding of the underlying biological mechanisms that mediate inflammatory arthritis in RA…
  • Abstract Number: 0763 • ACR Convergence 2020

    Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis

    Klára Prajzlerová1, Nora Petrovská1, Monika Gregová1, Jiří Baloun2, Petra Hánová2, Karel Pavelka1, Jiří Vencovský1, Ladislav Šenolt1 and Mária Filková1, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic

    Background/Purpose: The presence of antibodies against citrullinated proteins (ACPA) significantly increases the risk of developing rheumatoid arthritis (RA). EULAR characterised individuals with arthralgia suspicious for…
  • Abstract Number: 0936 • ACR Convergence 2020

    Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis

    Andrea Fava1, Jill Buyon2, Chandra Mohan3, Ting Zhang3, H. Michael Belmont4, Peter Izmirly5, Robert Clancy6, Jose Monroy-Trujillo7, Celine Berthier8, Anne Davidson9, Nir Hacohen10, David Wofsy11, Deepak Rao12, Soumya Raychaudhuri13, The Accelerating Medicines Partnership in SLE Network14, William Apruzzese15 and Michelle Petri16, 1Johns Hopkins University, Baltimore, MD, 2Department of Medicine, NYU School of Medicine, New York, NY, 3UT Houston, Houston, 4New York University, New York, NY, 5Department of Medicine, New York University School of Medicine, New York, NY, 6NYU School of Medicine, New York, 7Johns Hopkins University, Baltimore, 8University of Michigan, Ann Arbor, 9Northwell Health, New York, 10Broad Institute, Boston, 11University of California San Francisco, San Francisco, CA, 12Brigham and Women's Hospital, Boston, MA, 13Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 14Multiple Institutions, Multiple Cities, 15., Boston, 16Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Treatment of lupus nephritis relies on renal histopathological features. However, renal biopsies do not capture patient-specific active biological pathways. Urine proteomic biomarkers could revolutionize…
  • Abstract Number: 0953 • ACR Convergence 2020

    Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout

    Jacob Wozniak1, Ru Bryan2, David Gonzalez3 and Robert Terkeltaub4, 1UC San Diego, San Diego, CA, 2UCSD, San Diego, CA, 3UC San Diego, San Diego, CO, 4VA Medical Center/UC San Diego, San Diego, CA

    Background/Purpose: In gout, long-term xanthine oxidase inhibitor treat to target urate lowering therapy (XOIT2T) markedly reduces flares and synovitis, despite delayed resolution of tissue crystal…
  • Abstract Number: 1359 • ACR Convergence 2020

    Targeted Serum Proteomic Analysis Following Upadacitinib Treatment in Ankylosing Spondylitis Shows Robust Suppression of Innate and Adaptive Immune Pathways with Tissue Repair Modulation

    Thierry Sornasse1, In-Ho Song2, Timothy Radstake3 and Dennis McGonagle4, 1AbbVie Immunology Clinical Development, Redwood City, 2AbbVie Inc., North Chicago, IL, 3AbbVie Immunology Clinical Development, North Chicago, 4The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom

    Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to…
  • Abstract Number: 1809 • ACR Convergence 2020

    Serum Cytokine Profiling in Systemic Lupus Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Clusters

    Fabien Vincent1, Jannina Ong1, Alberta Hoi2, Sarah Boyd1, Hieu Nim1 and Eric Morand3, 1Monash University, Clayton, Victoria, Australia, 2Monash University, Melbourne, Victoria, Australia, 3Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: SLE is a heterogeneous disease, where a better understanding of molecular differences between patients is needed in order to direct therapy. Existing approaches generally…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences